Sorafenib treatment for recurrent stage T1 bilateral renal cell carcinoma in patients with Von Hippel-Lindau disease: A case report and literature review

被引：7

作者：

Choi, Kyung Hwa ^{[1
]}

Yu, Young Dong ^{[1
]}

Kang, Moon Hyung ^{[1
]}

Park, Dong Soo ^{[1
]}

机构：

[1] CHA Univ, CHA Bundang Med Ctr, Dept Urol, Songnam, South Korea

来源：

CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL | 2015年 / 9卷 / 9-10期

关键词：

SUNITINIB; PATTERNS; THERAPY;

D O I：

10.5489/cuaj.2863

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Renal cell carcinoma (RCC) with Von Hippel-Lindau (VHL) syndrome is associated with multiple recurrences and a young age at diagnosis. Therefore the primary goal of treatment is to stabilize the disease, minimizing the surgical resection and preserving the renal function in the patients with VHL who have developing RCC nodules after initial treatment. This is the first case report of VHL disease, with long-term stable disease, treated with a half dose of sorafenib after surgical resection and radiofrequency ablation for multiple recurrent stage T1 masses. We discuss the efficacy and safety of low-dose sorafenib treatment and review RCC in a patient with VHL disease.

引用

页码：E651 / E653

页数：3